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AbstrACt
Introduction Peripheral neuropathy is a major risk factor 
for falls in adults with diabetes. Innovative footwear 
devices which artificially manipulate the sensory 
environment at the feet, such as textured shoe insoles, 
are emerging as an attractive option to mitigate balance 
and walking problems in neuropathic populations. This 
study aims to explore whether wearing textured insoles for 
4 weeks alters balance performance in adults with diabetic 
peripheral neuropathy.
Methods and analysis A prospective, single-blinded 
randomised controlled trial with parallel groups will 
be conducted on 70 adults with diabetic peripheral 
neuropathy. Adults with a diagnosis of peripheral 
neuropathy (secondary to type 2 diabetes), aged ≥18 
years, ambulant over 20 m (with/without an assistive 
device), will be recruited. Participants will be randomised 
to receive a textured insole (n=35) or smooth insole 
(n=35), to be worn for 4 weeks. During baseline and 
post intervention assessments, standing balance (foam/
firm surface; eyes open/closed) and walking tasks will 
be completed barefoot, wearing standard shoes only, 
and two different insoles (smooth, textured). The primary 
outcome measure will be centre of pressure (CoP) 
velocity, with higher values indicating poorer balance. 
Secondary outcome measures include walking quality 
(gait velocity, base of support, stride length and double-
limb support time), physical activity levels, foot sensation 
(light-touch pressure, vibration) and proprioception (ankle 
joint position sense), and other balance parameters (CoP 
path length, anteroposterior and mediolateral excursion). 
Patient-reported outcomes will be completed evaluating 
foot health, frequency of falls and fear of falling. Data 
will be analysed using a repeated measures mixed 
models approach (including covariates) to establish any 
differences between-groups, for all outcome measures, 
over the intervention period.
Ethics and dissemination Ethical approval has been 
obtained from the institutional Human Research Ethics 
Committee (#2017000098). Findings will be disseminated 
at national and international conferences, through peer-
reviewed journals, workshops and social media.
trial registration number ACTRN12617000543381; Pre-
results.
IntroduCtIon
Peripheral neuropathy affects between 22% 
and 51% of people with diabetes,1 2 and is 
a major risk factor for falls, reported to be 
present in the lower limbs of up to 86% of 
older diabetic fallers.3 Nerve damage can 
severely disrupt the quality of sensory infor-
mation transmitted from the feet to the brain, 
which provides vital cues about the supporting 
surface and position of body segments, to 
help older people remain upright. Similarly, 
balance impairments can also be observed 
in younger adults with diabetic peripheral 
neuropathy, placing them too at risk of 
sustaining falls-related injuries, with potential 
for deterioration with increasing age.4 Loss of 
cutaneous sensory information from the foot 
sole is reported to be a critical factor contrib-
uting to walking instability, poor balance5 
and falls,6 in people with diabetic peripheral 
neuropathy.
strengths and limitations of this study
 ► This study will be among the first to explore whether 
novel shoe insoles can provide substitute sensory 
input to the soles of the feet, to help mitigate bal-
ance problems in adults with diabetic peripheral 
neuropathy.
 ► If the trial demonstrates a positive effect of textured 
insoles, the findings will be used to inform the de-
velopment of innovative, affordable, non-invasive 
neuropathic treatment devices, which target diabet-
ic foot sensory complications that contribute to falls.
 ► This study is limited to assessing the effects of 
wearing textured insoles for 4 weeks on balance, 
walking, physical activity and patient-reported out-
comes: exploration of long-term wear, whereby any 
beneficial effects may accrue over time, will be test-
ed in future trials.
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Foot care is a standard practice in the management 
of diabetic populations, with shoe insoles routinely 
prescribed by healthcare professionals to help prevent 
foot ulceration,7 8 or provide pain relief, by way of redis-
tributing plantar pressures. The effect of traditional 
footwear devices on balance performance in people 
with diabetic peripheral neuropathy has received little 
attention, with inconclusive evidence both supporting9 10 
and refuting,11 the efficacy of shoe insoles. In contrast, 
lower limb strengthening exercises demonstrate stronger 
evidence as an effective balance intervention for people 
with diabetic neuropathy,9 which may also have the 
capacity to improve cutaneous reinnervation.12 However, 
innovative footwear devices which artificially manipu-
late the sensory environment at the feet are emerging as 
an attractive treatment option, which may compliment 
current exercise strategies to help mitigate balance and 
walking problems and reduce the risk of falling in adults 
with diabetes.13–15 Textured shoe insoles, designed to 
stimulate cutaneous receptors on the soles of the feet and 
provide enhanced sensory feedback, have been shown to 
improve lateral (sideways) standing balance in healthy 
older adults,13 and those with Parkinson’s disease.16 
This is a clinically important finding, as lateral balance 
is reported to be a strong predictor of falls.17 18 Further-
more, in older fallers,14 and adults with multiple scle-
rosis,19 wearing textured insoles have also brought about 
changes in spatiotemporal gait measures, synonymous 
with more confident and stable walking patterns.
The potential therapeutic effects of textured insoles 
in people with pathological sensory loss largely remain 
unknown, due to the exclusion of this population from 
previous research strategies. However, a systematic review 
by Paton et al20 revealed that people with pathological loss 
of foot sensation may benefit most from wearing footwear 
devices which augment the plantar sensory environment. 
There is limited evidence exploring the concept of lower 
limb sensory devices for adults with diabetic peripheral 
neuropathy.10 21 22 One study applied tactile stimulation to 
the calf, therefore bypassing critical foot regions showing 
neuropathic damage.22 A further study explored insoles 
comprising in-built, battery-powered, vibrating mecht-
rodes10: a design feature which is impractical, complex 
to integrate into everyday footwear and expensive as 
a neuropathic treatment. Paton et al21 provided new 
evidence to demonstrate that wearing textured insoles 
may heighten reliance on, and responsiveness to, plantar 
sensory inputs even in the presence of severe diabetic 
peripheral neuropathy. Further, compelling evidence by 
Wegener has demonstrated that wearing sensorimotor 
foot orthoses can alter ankle, knee and hip motion during 
walking, which may translate to increased gait stability, in 
adults with inherited neuropathy (Charcot-Marie-Tooth 
disease).23 This area urgently requires investigation in 
the real world context to understand the clinical impact 
in people with diabetic peripheral neuropathy. Textured 
insoles may offer a new rehabilitative approach, which 
promotes self-management by the user, to improve 
balance and walking, and reduce the risk of falling, in 
adults with diabetes.
study aims
This study protocol describes a randomised controlled trial 
of textured insoles, worn over a 4-week period, in adults 
with diabetic peripheral neuropathy. The primary aim of 
the study is to determine if wearing textured insoles for 
4 weeks alters measures of standing balance ability (centre 
of pressure (CoP) velocity), under different conditions 
where visual information and the supporting surface are 
manipulated. Secondary aims are to determine if short-
term wear of textured insoles leads to changes in walking 
quality (spatiotemporal gait parameters: gait velocity, base 
of support, stride length and double-limb support time), 
foot sensation (light touch pressure, vibration, ankle joint 
proprioception), physical activity levels using wearable 
sensors, other standing balance parameters (CoP path 
length, anteroposterior and mediolateral excursion) and 
patient-reported outcomes (foot-health specific quality of 
life, frequency of self-reported falls and fear of falling).
MEthods And AnAlysIs
study design
A prospective, parallel group, single-blinded, randomised 
controlled trial with 70 community-dwelling adults, living 
with diabetic peripheral neuropathy will be conducted 
and reported, conforming to the Standard Protocol Items 
for Randomised Trials statement (figure 1).24
location and setting
All assessments will be conducted within the Centre 
for Neurorehabilitation, Ageing and Balance Research 
gait laboratory at The University of Queensland (UQ), 
Australia.
Participants
Recruitment of participants commenced on 14 August 
2017 and remains ongoing. Community-dwelling men 
and women with a clinical diagnosis of diabetic peripheral 
neuropathy secondary to type 2 diabetes will be identified 
through a pool of sampling frames including Diabetes 
Australia, Diabetes Queensland and local community 
organisations across the Brisbane, Gold Coast, Sunshine 
Coast and Logan regions, via mainstream media adver-
tisements, including social media (eg, Facebook). Partic-
ipants will also be identified through research volunteer 
databases maintained by the Centre for Neurorehabilita-
tion, Ageing and Balance Research at UQ and Movement 
Neuroscience Programme at Queensland University 
of Technology (QUT); UQ and QUT Health Clinics, 
whereby recruitment processes will be coordinated by 
clinical staff to maintain patient confidentiality.
Participants will be permitted to take part in the trial if 
they meet the following criteria: aged  ≥18 years; clinical 
diagnosis of diabetic peripheral neuropathy secondary 
to type 2 diabetes; ambulant over 20 m (with or without 
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Figure 1 Trial design.
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the use of an assistive device, eg, single cane); willing to 
wear shoe insoles for 4 weeks; and have adequate English 
communication skills to provide informed consent 
and comprehend the study procedures. A diagnosis 
of diabetic peripheral neuropathy will be determined 
using one of two criteria. First, participants will be asked 
to provide details of their diagnosis of type 2 diabetes 
and peripheral neuropathy, previously given by a health 
professional. Second, participants who have a diagnosis 
of type 2 diabetes, but not of peripheral neuropathy, yet 
self-report significant alterations in lower limb sensation 
synonymous with neuropathy, will be screened using the 
Diabetic Neuropathy Symptom Score to determine eligi-
bility.25 This tool comprises four items addressing the 
nature and frequency of neuropathic symptoms (expe-
rienced across both lower limbs collectively) including 
(1) unsteadiness in walking; (2) burning, aching pain or 
tenderness in the legs or feet; (3) prickling sensations in 
the legs or feet and; (4) numbness in the legs or feet, 
experienced in the last 2 weeks. The presence of one 
symptom is scored as 1 point, and a total score of 1–4 
points indicates the presence of peripheral neuropathy. 
This tool has comparable sensitivity (79%) and higher 
specificity (78%) compared with physical examination 
techniques (monofilaments: 81% sensitivity, 56% spec-
ificity; vibration perception threshold: 81% sensitivity, 
58% specificity),25 and is recommended by Diabetes 
Australia and The Royal Australian College of General 
Practitioners,26 as a method for confirming a diagnosis 
of peripheral neuropathy. Exclusion criteria are current 
foot ulceration or other lower limb injury; current use 
of over-the-counter or custom-made foot orthoses or 
shoe insoles; previous history of lower limb or partial 
foot amputation, Charcot Arthropathy, other neurolog-
ical diseases or cardiorespiratory conditions that limit 
ambulation; unstable psychiatric condition (defined by 
a qualified health professional, eg, general practitioner) 
or cognitive impairment (Short Form Mini-Mental State 
Examination Score <24).27 All participants will initially be 
screened via telephone interview, prior to attending face-
to-face assessments.
randomisation and blinding
Participants will be randomised to either the textured 
(intervention) insole or smooth (control) insole group. 
The concealed, computer-generated block randomisation 
schedule will be managed by an independent offsite inves-
tigator who is not involved in the enrolment or assessment 
of participants. Consecutively numbered, opaque enve-
lopes, containing group allocation (in a 1:1 ratio), will be 
opened after the baseline assessment by the study podia-
trist (JNM) who is solely responsible for fitting and issuing 
the insoles. All other investigators and research assistants, 
responsible for enroling and assessing participants, will 
remain blind to the group allocation. Following baseline 
assessment, the first and second research assistants will 
leave the gait laboratory to ensure blinding to the insole 
condition. The podiatrist will then customise and fit the 
participant with their allocated insole, and provide advice 
regarding the frequency of wear, completion of insole 
wear and falls diaries. Participants will be instructed not 
to divulge their insole allocation. The second research 
assistant will be responsible for maintaining the with-
in-session insole condition randomisation schedule and 
coding, and for fitting the different insoles and shoes 
during assessments. During baseline assessment and 
post intervention assessment, the first research assistant 
will remain blinded to the order of testing of insole condi-
tions. Due to the nature of the insole material being used, 
it is not possible to blind participants to their allocated 
group (ie, those in the intervention group may perceive 
the textured surface against their foot or visibly see the 
geometric pattern on the upper surface of the insole), 
therefore, the identity of the intervention insole will not 
be concealed. Participants will not be informed which 
insole condition is intended to provide enhanced plantar 
sensory feedback or is under investigation for its capacity 
to alter balance performance. Debriefing of participants 
will occur on completion of the trial. Additionally, partici-
pant coding will not refer to group allocation.
Intervention
Two different shoe insoles will be investigated in this 
randomised controlled trial: textured (intervention) 
insoles and smooth (control) insoles (figure 2). Impor-
tantly, both insoles have been implemented in previous 
research strategies,21 and incorporate materials typi-
cally used for insoles prescribed to people with diabetic 
peripheral neuropathy. The insoles will be custom-made 
to each participant’s foot and shoe length. The textured 
insole will be constructed from 3.2 mm Poron (Poron 
4000, Algeos, VIC, Australia), covered with 100% poly-
vinyl chloride (PVC) material which has raised pyramidal 
nodules (Techno PVC covering, Black Tech, Algeos, VIC, 
Australia) with centre-to-centre distances of 9 mm. The 
Figure 2 Textured and smooth shoe insoles.
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PVC material will be adhered to the Poron base using 
contact adhesive (Selley’s Kwik Grip Crystal Clear, Delux-
Group, VIC, Australia). The textured zone will extend 
from the heel to the proximal aspect of the first–fifth 
metatarsal heads, to avoid excessive friction at the fore-
foot.28 To minimise increased pressure that could lead to 
skin damage at the exposed edge of the textured mate-
rial, a forefoot extension (1 mm, Poron 4000) will be 
adhered to the Poron base, extending proximal to the 
metatarsal heads to the distal end of the insole. This fore-
foot extension will be bevelled to create a smooth transi-
tion from the textured zone. The length of the textured 
zone and forefoot extension will be customised to each 
participant, by the podiatrist (JNM) at the baseline assess-
ment. The smooth insole will only comprise the 3.2 mm 
Poron (with no PVC top cover). All edges of the textured 
and control insoles will be smoothed and shaped to fit 
the intended footwear using an orthopaedic grinder 
prior to dispense. Participants will be instructed to wear 
their allocated insoles, in their own shoes, as much as 
possible (when indoors and outdoors): wear time will be 
gradually increased. Assessments of balance and gait will 
be conducted with participants wearing standard shoes 
(following a 5 min familiarisation period) used in our 
previous work,16 29 comprising a basic construct rubber-
soled shankless shoe with a soft canvas upper (Volley 
International Canvas, Volley, China), into which the 
insoles will be inserted. This standardisation will control 
for any possible insole/shoe interactions which could 
influence the findings. The shoes will be available in a 
range of sizes. Participants in both groups will be advised 
to continue with their usual care, and that athletic socks 




The primary outcome measure will be CoP velocity 
(mm.s– 1) during bilateral standing, providing a measure 
of unperturbed balance control. CoP velocity represents 
the speed at which the body’s centre of mass is moving, 
with a higher value indicating more rapid and poten-
tially unstable movement.30 Participants will stand on 
an AMTI force platform (sampling rate 1000 Hz), using 
standardised foot positioning (heels placed 1/10th 
participants height apart and angled to 14°),31 with arms 
hanging by their sides,13 for 30 s. Standing balance will 
be performed on a firm and foam (50×41×15 cm foam 
block, placed directly on top of the force platform) 
surface, with eyes open and eyes closed, each while bare-
foot, wearing standard shoes only, and when wearing 
two different insoles (textured, smooth) within standard 
shoes (three trials per condition). The effects of texture 
may be more clearly identified during challenging tests of 
balance, which include the use of unstable surfaces such 
as foam.15 16 During eyes open trials, participants will be 
instructed to look straight ahead at a black, circular visual 
target (15 cm diameter), located 2.5 m from the centre 
of the force platform and adjusted to each participants’ 
eye level. The test sequence (shoe condition, surface and 
vision) will be randomised. Where a participant overbal-
ances or moves out of the standardised positioning, the 
trial will be discarded and repeated.
secondary outcome measures
Spatiotemporal gait parameters
Spatiotemporal gait parameters will be evaluated as a 
measure of walking quality, including gait velocity, medi-
olateral base of support, stride length and double-limb 
support time (and step-to-step variability of each param-
eter). Level-ground gait performance will be evaluated 
by completing a 10 m walk over an instrumented, vinyl 
walkway (GAITRite CIR Systems, USA). The GAITRite 
has been shown to have high reliability.32 33 A start and 
finish line will be marked on the floor 0.63 m in front and 
0.63 m behind the walkway to allow participants to accel-
erate and decelerate outside the walkway.32 Five walking 
trials will be completed at participants’ comfortable, 
self-selected pace, while barefoot, wearing standard shoes 
only and wearing two different shoe insoles (textured, 
smooth) within standard shoes. Participants will be 
instructed to look straight ahead while walking. The test 
sequence (footwear condition) will be randomised.
Physical activity
Habitual physical activity levels will be measured over 
seven consecutive days, using a small wireless activity 
monitor (ActivPAL, Glasgow, Scotland), on two separate 
occasions: 1 week prior to the administration of insoles and 
during the final week of the 4-week intervention period.34 
Measures of physical activity (per hour) will include time 
spent sitting, standing, stepping (minutes); number of 
sit-to-stand and stand-to-sit transitions; number of steps 
taken and; energy expenditure (metabolic equivalent). 
Previous evidence has demonstrated that the ActivPAL is a 
reliable and valid device for measuring posture and move-
ment in adults during daily physical activities,35 including 
walking.36 The increasing use of accelerometry in people 
with peripheral neuropathy is attributed to its ability to 
allow monitoring of changes in walking impairments with 
disease progression.37 38 Activity data provide the ultimate 
measure of participation as it pertains to gait, so provides 
a vital measure to determine if textured insoles impact on 
daily activities.
Foot sensation and proprioception
Lower limb somatosensory function will be assessed 
bilaterally. Light touch-pressure sense will be deter-
mined by recording the smallest monofilament that the 
participant can perceive at five locations on each foot.39 
Semmes-Weinstein monofilaments (1.65–6.65 gauges) 
will be used to determine tactile sensibility at the hallux, 
first and fifth metatarsal head, heel and dorsal foot.39 40 
Monofilaments will be applied on three occasions per 
site, perpendicular to the skin for 1.5 s, and the smallest 
perceived (≥2/3 applications) indicating the participant’s 
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light-touch pressure sense threshold. Vibration percep-
tion will be assessed using a neurothesiometer (Briggate 
Medical Company, VIC, Australia) (frequency 100 Hz, 
amplitude 0–50 V), at the hallux and first metatarsopha-
langeal joint. Starting at 0 V, the vibration will be gradually 
increased until the participant indicates they can feel the 
vibration (normal: ≤25 V).41 The average of three read-
ings will be calculated, per site. Foot position awareness 
(proprioception) will be assessed using the ankle joint 
angle reproduction test,42 to help determine whether 
textured insoles improve dorsiflexion and plantarflexion 
perception, which may translate to improved toe clear-
ance during walking. The participant’s ankle joint will 
be passively set (by the investigator) to three angles in 
plantarflexion and dorsiflexion directions, relative to a 
neutral foot position. To minimise extraneous cues and 
psychological processes that could influence the findings, 
the foot will be positioned at a variable time and trajec-
tory. The participant will be asked to reposition the ankle 
joint at the target angle by moving only the foot segment. 
Accuracy in joint positioning will be determined by 
measuring the difference between the target and actual 
angles using an internet-based goniometer, which has 
high inter-rater (ICC2, 1=0.96 to >0.99) and intra-rater 
(ICC=all >0.99) reliability for measuring joint angles.43
CoP movement
Additional secondary measures of standing balance will 
include CoP path length (mm), anteroposterior and 
mediolateral excursion (range and SD, mm). Previous 
evidence in people with multiple sclerosis44 has demon-
strated significant effects of wearing textured insoles 
within shoes, compared with wearing shoes only, 
including immediate reductions in mean CoP path 
length (the absolute length of CoP path movement) by 
19.3% and sway rate (the mean speed of CoP movement) 
by 25.2%, during quiet standing with eyes closed at base-
line assessment.
Patient-reported outcomes
Patient-reported outcomes will include the Foot Health 
Status Questionnaire (FHSQ), a measure of self-per-
ceived foot-health specific quality of life, before and after 
an intervention.45 The tool contains a total of 29 items 
(Likert scales and open-ended responses), of which 13 
items address foot health, 6 items consider general health 
and 10 items address demographic and social factors. 
The tool has established content and criterion validity,46 
as well as reliability.45 Further, the FHSQ has been shown 
to be responsive to change when measuring the effects of 
shoe insoles,47 and footwear interventions.48 Number of 
self-reported falls in the previous 12 months will also be 
recorded, and fear of falling assessed using the Falls Effi-
cacy Scale-International (FES-I).49 The FES-I is a 16-item 
tool which measures the level of concern experienced in 
relation to a range of activities of daily living. This tool 
has evidence for its convergent, predictive and internal 
validity and reliability,50 51 as well as responsiveness.52
Participants will also be followed for 4 weeks with insole 
wear self-reported diaries and falls calendars,53 to deter-
mine: (1) number of waking hours per day the insoles 
are worn and; (2) frequency, time, location of any falls/
injuries and what (if any) medical attention was sought.29
Procedures
Baseline assessment
On enrolment into the study, and following informed 
consent, participants will be mailed a series of question-
naires and a small wireless activity monitor (including 
instructions concerning the attachment and operation of 
the monitor). Demographics including sex, date of birth, 
height, weight, body mass index, medical history, current 
medications and diabetes duration will be collected, in 
addition to the patient-reported outcomes described 
above. Participants will be asked to wear the activity 
monitor for seven consecutive days, following which they 
will attend UQ for their baseline assessment. At this time, 
participants will return their completed questionnaires 
and activity monitor to the investigators. Balance, gait, 
foot sensation and proprioception will be assessed. To 
minimise the potential effects of fatigue, participants will 
be offered regular rests, and testing will be conducted at 
a similar time of day across the two sessions.
Post intervention assessment
Balance, gait, foot sensation, proprioception, self-re-
ported foot health and fear of falling will be assessed 
within 2 weeks of the end of the 4-week intervention 
period, using the same procedures as at baseline. Phys-
ical activity will be monitored for a second time, over 
seven consecutive days, (ActivPAL mailed out at week 3, 
returned in person at the week 4 assessment). A 4-week 
intervention period is consistent with previous footwear 
intervention trials and will provide maximal time for 
the: (1) accrual of any sensorimotor training effects and 
(2) accumulation of meaningful changes in outcome 
measures related to balance performance. This final 
point of assessment will (1) quantify whether any imme-
diate changes in balance and gait, observed at baseline, 
have accrued over time, or if additional effects can be seen 
and; (2) determine whether there are any alterations in 
physical activity levels, foot sensation or proprioception 
(which may suggest the insoles have a sensory training 
effect) or patient-reported outcomes. At the completion 
of the 4-week intervention, participants will be asked to 
rate the comfort of wearing their allocated insoles using a 
100 m visual analogue scale anchored at 0 mm (extremely 
uncomfortable) and 100 mm (extremely comfortable).54 
The perceived comfort rating scale has been previously 
validated and reported to be a reliable measures of foot-
wear comfort.54 Participants will also be asked to return 
their insole-wear and falls diaries at this time.
statistical analysis
Sample size was calculated for the primary outcome 
measure of CoP velocity, using data from Kalron et al,44 
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who reported between-condition differences (shoes only 
and shoes + textured insole) that equated to an effect size 
of 0.72. Based on these data, 32 participants per group will 
provide sufficient power to detect differences in balance 
of a similar magnitude (α=0.05, β=0.20). We will allow for 
a 10% attrition rate over the 4-week intervention period, 
and recruit 35 participants per group.
Demographic and clinical data will be described as mean 
(SD) for continuous data and n (%) for categorical data. 
All analyses will be conducted in a blinded manner (by 
ALH, who will remain blinded to group allocation), on an 
intention-to-treat basis, with the level of significance set to 
0.05. At the end of the trial, a blind review of the data will 
be undertaken to consider the inclusion of covariates and 
the appropriateness of imputing any missing data. Where 
possible, reasons for missing data will be ascertained and 
reported (eg, voluntary withdrawal, loss to follow-up). 
All statistical analyses will be performed using SPSS V.24. 
Data will be examined for normality and homogeneity of 
variance. To establish any differences between the inter-
vention and control groups for all outcome measures, a 
repeated measures mixed-models approach will be under-
taken using data at baseline and 4 weeks. Non-parametric 
tests will be used where data are not normally distributed 
or violates the assumption of sphericity. A priori covari-
ates will include age, gender, physical activity levels and 
insole wear time.
data management
All data collected during the study will be stored securely 
(locked filing cabinets, password-protected computers) 
and confidentially (using a unique identification code) 
on paper and electronically at UQ, and will only be acces-
sible to the investigators. Following the study, data will be 
stored for at least 10 years.
Patient and public involvement
In our previous studies of textured shoe insoles, we 
received feedback from patients about their experiences 
and perceptions of wearing our insoles and completing 
the assessment procedures, which guided the design of 
the current study and development of the intervention. 
Patients were not involved in the development of the 
research question, outcome measures or the recruit-
ment of participants. We will assess the burden of the 
insole intervention on patients by collecting informa-
tion about adverse events and the number of hours the 
insoles were worn. The results of the study will be dissem-
inated to patients via media releases through Diabetes 
Australia (and its state-specific organisations, eg, Diabetes 
Queensland).
Ethics and dissemination
Written informed consent will be obtained from all partic-
ipants prior to enrolment.
There are minimal risks associated with this study. The 
textured and smooth insoles will be constructed from 
materials used in standard insoles traditionally issued to 
people with diabetic peripheral neuropathy. The allo-
cated insole will not be fitted if it is markedly uncomfort-
able for the participant to wear, to minimise any adverse 
reactions.
Exposure to a new insole could lead to dermatological, 
musculoskeletal or sensory changes to the feet, or issues 
related to insole-fit and durability. Subsequently, all partic-
ipants will receive contact details for podiatry care, and an 
insole advice leaflet. Participants who develop adverse foot 
events (eg, ulceration) will be withdrawn from the trial. 
Similarly, should wearing insoles increase the prevalence 
of falls experienced during the intervention period (rela-
tive to the frequency of falls experienced in the previous 
12 months), all participants to whom this concerns will be 
withdrawn from the study, and their general practitioner 
notified. All adverse events will be reported in line with 
university ethical governance standards.
During balance and walking tests, while wearing unfa-
miliar shoes and insoles, participants could experience 
a change in their stability. Therefore, participants will 
be closely supervised by the investigators. As part of the 
screening assessment, participants will be required to 
report on personal pain, disease and injury. This may 
require disclosure of the cause of impairment, or recol-
lection of traumatic events (eg, injurious fall), which 
could be a potential cause of distress. Participants will 
be advised that they can choose not to answer any ques-
tionnaire items, and that this decision will not affect their 
involvement in the trial.
The findings will be disseminated at national and inter-
national conferences and through peer-reviewed jour-
nals. Patients, healthcare professionals and the public will 
be informed of the findings via workshops, local meetings 
and social media.
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